UPDATED: Amgen’s Kyprolis beats Janssen’s Velcade in multiple myeloma trial
Amgen’s Kyprolis has beaten Janssen’s Velcade on progression-free survival in patients with relapsed or refractory multiple myeloma taking part in the Phase III Endeavor trial.
Read More




